Colorado § 25-45-102 Legislative declaration

Colorado Statutes

§ 25-45-102 — Legislative declaration

Colorado § 25-45-102

Title 25Public

Art.Access to Treatments for Terminally Ill Patients

This text of Colorado § 25-45-102 (Legislative declaration) is published on Counsel Stack Legal Research, covering Colorado primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Colo. Rev. Stat. § 25-45-102 (2026).

Text

(1)For purposes of this part 1, the general assembly finds and declares that:

(a)The process of approval for investigational drugs, biological products, and devices in the United States protects future patients from premature, ineffective, and unsafe medications and treatments over the long run, but the process often takes many years;

(b)Patients who have a terminal illness do not have the luxury of waiting until an investigational drug, biological product, or device receives final approval from the United States food and drug administration;

(c)Patients who have a terminal illness have a fundamental right to attempt to pursue the preservation of their own lives by accessing available investigational drugs, biological products, and devices;

(d)The use of available investig

Free access — add to your briefcase to read the full text and ask questions with AI

(1) For purposes of this part 1, the
general assembly finds and declares that:

(a) The process of approval for investigational drugs, biological products,
and devices in the United States protects future patients from premature,
ineffective, and unsafe medications and treatments over the long run, but the
process often takes many years;

(b) Patients who have a terminal illness do not have the luxury of waiting
until an investigational drug, biological product, or device receives final approval
from the United States food and drug administration;

(c) Patients who have a terminal illness have a fundamental right to attempt
to pursue the preservation of their own lives by accessing available investigational
drugs, biological products, and devices;

(d) The use of available investigational drugs, biological products, and
devices is a decision that should be made by the patient with a terminal illness in
consultation with the patient's health-care provider and the patient's health-care
team, if applicable; and

(e) The decision to use an investigational drug, biological product, or device
should be made with full awareness of the potential risks, benefits, and
consequences to the patient and the patient's family.

(2) It is the intent of the general assembly for this part 1 to allow for
terminally ill patients to use potentially life-saving investigational drugs, biological
products, and devices.

Legislative History

Source: L. 2014: Entire article added, (HB 14-1281), ch. 220, p. 823, � 1, effective May 17. L. 2025: IP(1) and (2) amended, (HB 25-1270), ch. 211, p. 953, � 1, effective May 19.